Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 16;12:10156. doi: 10.1038/s41598-022-14247-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

21–22Us with a 5′ monophosphate associated with parasitism. (a) Length distribution and 5′ starting nucleotide of 13–30 nt sRNAs with a 5' modification originating from either protein-coding genes, intergenic spaces or transposable elements, that are significantly more abundant in the PF (n = 6506 sequences), FLF (n = 1945 sequences) or not DE (n = 3549 sequences). (b) Predicted targets of significantly more abundant 21–22Us in the PF, FLF and non-DE based on antisense sequence complementarity. Targets include protein-coding genes (CDS, 5′UTR and 3′UTR) and TE sequences. (c) Classification of predicted TE targets of 21–22Us in the PF. Targets include TcMar-Mariner DNA transposon (48.5%), LTR retrotransposons (10.8%) and an unclassified family (38.6%). (d) Enriched GO terms based on the biological function (BF) of the 21–22U predicted target genes. Clustering of the GO terms based on similar functions was carried out using REVIGO. Size of circle indicates the number of genes and colour indicates p-value. (e) Difference in expression level (RPKM: FLF minus PF) of genes putatively targeted by PF-overexpressed 21–22Us. The targeted genes were more highly expressed in the FLF cf. PF stage. (f) Expression of TEs either predicted to be targeted or not targeted by PF-overexpressed 21-22Us. *Indicates p < 0.01. RPKM = Reads per kilobase million; TPM = Transcripts per kilobase million.

HHS Vulnerability Disclosure